Ringing in a New Year by helping save someone’s life.
It was New Year’s Day when a large, academic medical facility needed a large dose of Factor VII within six hours to help save the life of a trauma patient. Read more
BioCARE is excited to announce that Octapharma's NUWIQ is now available.
Nuwiq is the first and only recombinant FVIII produced in human cells without chemical modification.
It is indicated in children and adults with Hemophilia A for on-demand treatment & control of bleeding disorders, perioperative management of bleeding and routine prophylaxis to reduce the frequency of bleeding episodes.
It is not indicated for the treatment of von Willebrand Disease.
To order this product, call BioCARE at 1-800-304-3064.
BioCARE announced that it has been named by Bio Products Laboratory Limited (BPL) as a distributor for Coagadex (coagulation factor X, human).
Coagadex was approved by the U.S. Food and Drug Administration (FDA) on Oct. 20, 2015. Coagadex is the first and only FDA-approved product to treat hereditary factor X deficiency, and is the only factor X concentrate available in the U.S.
Factor X ("ten") deficiency is a rare, inherited bleeding disorder caused by inadequate levels of clotting factor X protein in the blood. Similar to hemophilia A and hemophilia B, factor X deficiency is characterized by episodes of prolonged spontaneous bleeding. As one of the rarest bleeding disorders, it affects approximately 300 to 600 patients in the U.S. The goal of treatment in patients with hereditary factor X deficiency is to replace their missing factor X without adding other clotting factors the patients do not need.
"Being selected as a distributor of Coagadex shows the trust BPL has in the excellent services BioCARE provides for its customers," said Linda Matthews, President of BioCARE. "As a long-time supporter of the bleeding disorders community, we are excited to continue our partnership with BPL by distributing this ground-breaking product."
To ensure a high level of service to providers of this patient community, BioCARE staff will receive specialized disease state and Coagadex product training from BPL.
BioCARE anticipates Coagadex to be available in December 2015.
Please see the full prescribing information for Coagadex at www.coagadex.com.
BioCAREhas been selected by Baxter as the exclusive, national authorized distributor for OBIZUR, the only recombinant porcine sequence factor VIII replacement treatment for acquired hemophilia A (AHA). OBIZUR was approved by the FDA for the treatment of bleeding episodes in adults with AHA, a very rare and potentially life-threatening acute bleeding disorder.
Linda Matthews, president of BioCARE, said, “We appreciate Baxter’s confidence in our organization and our customer- and patient-focused approach. Our unique high-touch service model has earned BioCARE a reputation among manufacturers, hospitals, treatment centers, physicians, and patients for integrity, reliability and innovation. This is an important relationship for the treatment of AHA.”
OBIZUR is offered in single-use vials that are available in 10-vial, 5- vial and 1-vial packages and is for intravenous injection after reconstitution.
For more information about the efficacy and safety of OBIZUR, clickOBIZUR_PI
The USDSCSA (United States Drug Supply Chain Security Act) requires product and transaction information for all sales of prescription drug products sold by a distributor or manufacturer effective July 1, 2015.
Manufacturers and distributors are required to provide the following:
Transaction Information (name of product, strength and dosage form, NDC, container size, name and address of the seller and the purchaser)
Transaction History (paper or electronic statement that include the transaction information for each prior transaction back to the manufacturer),
Transaction Statement (paper or electronic attestation by the entity transferring ownership of the product that is authorized under the Act, received the products from an authorized party, and other DSCSA specified information).
BioCARE has partnered with a group called TraceLink to provide an easy, electronic solution for you to view and download any information you need related to BioCARE products that you have purchased. Our customers will be receiving an email soon from TraceLink asking you to create an account. This is free of charge and will allow you to access the TraceLink portal at any time to view your transaction history. For more information, visit TraceLink
If you have any questions about your account, please contact our Customer Service department at 1-800-304-3064. For additional information on the USDSCSA, please visit this website.
Blood Systems, the parent company of BioCARE, has been selected by Arizona Business Magazine and BestCompaniesAZ as one of 40 winners of the 2015 Arizona’s Most Admired Companies Awards (MAC) and is featured in the September/October issue of the magazine.
Arizona’s Most Admired Companies are selected based on performance in the following areas: Workplace Culture, Leadership Excellence, Corporate and Social Responsibility, Customer Opinion and Innovation.
“This is the most comprehensive and most prestigious corporate awards program in Arizona. It recognizes the contributions and impact these ‘most admired companies’ bring to the state,” says Denise Gredler, Founder & CEO of BestCompaniesAZ and co-founder of the MAC program.
“Every day, I am proud of and inspired by the Blood Systems team,” says Dan Connor, Blood Systems President and CEO. “I am delighted that BestCompaniesAZ chose to honor my co-workers for their commitment to the donors, patients and communities we serve and for the way they live our values of respect, integrity, teamwork and excellence.”
Blood Systems—one of the nation’s oldest and largest non-profit community blood service providers—operates community blood centers serving more than 700 hospitals in 22 states, BioCARE's biological products distribution services, a quality consulting group and the world-renowned transfusion medicine research institute, Blood Systems Research Institute and is a partner in the operation of high-volume donor testing laboratories, Creative Testing Solutions.
Specialty pharmaceutical distributor BioCARE announced that it was awarded the contract to offer GPO compliant services to acute and non-acute members of MedAssets. The contract became effective on March 1, 2015.
“We are very excited about this affiliation as a viable option to members of MedAssets,” said Linda Matthews, President of BioCARE. “We know that our unique high-touch service model will be just one of the many benefits to offer to MedAssets’ members.”
Headquartered in Alpharetta, Georgia, MedAssets is a performance improvement company focused on helping providers realize financial and operational gains so that they can sustainably serve the needs of their community.
For more information about MedAssets, visit www.medassets.com.
BioCARE is a specialty distributor based in Phoenix Arizona. BioCARE has been delivering speciality and therapeutic biological products to customers since 1982, and has the expertise and networks to allow products to be available for same day and STAT delivery.